Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to $1.3 million.

  • Metagenomi's Gains from Investment Securities rose 199417.89% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 199417.89%. This contributed to the annual value of $63940.0 for FY2024, which is 9932.62% down from last year.
  • Per Metagenomi's latest filing, its Gains from Investment Securities stood at $1.3 million for Q3 2025, which was up 199417.89% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Metagenomi's Gains from Investment Securities ranged from a high of $30.6 million in Q1 2023 and a low of $63940.0 during Q1 2024
  • Its 3-year average for Gains from Investment Securities is $3.8 million, with a median of $108089.0 in 2025.
  • As far as peak fluctuations go, Metagenomi's Gains from Investment Securities tumbled by 9979.11% in 2024, and later soared by 199417.89% in 2025.
  • Quarter analysis of 3 years shows Metagenomi's Gains from Investment Securities stood at $228000.0 in 2023, then crashed by 71.96% to $63940.0 in 2024, then skyrocketed by 1994.18% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.3 million for Q2 2025, and $108089.0 during Q1 2025.